+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis



Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis



Molecular Neurobiology 2019



Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease for which the existing candidate biomarkers (neurofilaments) have low specificity. Changes in blood IgG N-glycosylation have been observed in several diseases, including ALS, whereas cerebrospinal fluid (CSF) IgG has been less studied. Here, we characterized N-glycans of CSF IgG from ALS patients in comparison with a control group of other neurological diseases. Cerebrospinal fluid was collected from patients with ALS (n = 26) and other neurological diseases (n = 10). N-Glycans were released from CSF purified IgG with peptide N-glycosidase F, labeled with 2-aminobenzamide and analyzed by NP-HPLC chromatography in combination with exoglycosidase digestion and MALDI-TOF mass spectrometry. The N-glycosylation profile of ALS CSF IgG consisted of diantennary N-glycans predominantly with proximal fucose and some bisecting GlcNAc; agalacto-, mono-, and digalactosylated as well as α2,6-sialylated structures were detected. Differences between ALS and control patients were observed; most relevant was the increase in ALS CSF IgG of the level of galactosylated structures defined here as Gal-index (median 46.87 and 40.50% for ALS and controls, respectively; p = 0.006). The predictive value of the Gal-index (AUC = 0.792, p = 0.007) considering ROC analysis had potential utility as a diagnostic test for ALS and was comparable to that of phosphoneurofilament heavy chain (AUC = 0.777, p = 0.011), which was used as benchmark marker for our group of patients. The results provide the basis to further explore the potential of IgG N-glycan galactosylation as biomarker for ALS by using larger cohorts of patients and controls.

(PDF emailed within 0-6 h: $19.90)

Accession: 066116614

Download citation: RISBibTeXText

PMID: 30674035

DOI: 10.1007/s12035-019-1482-9


Related references

Can Oxidation-Reduction Potential of Cerebrospinal Fluid Be a Monitoring Biomarker in Amyotrophic Lateral Sclerosis?. Antioxidants and Redox Signaling 28(17): 1570-1575, 2017

Neurofilament heavy subunit in cerebrospinal fluid: a biomarker of amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis 12(2): 144-147, 2011

Is cerebrospinal fluid obtained for diagnostic purpose a good material for biomarker studies in amyotrophic lateral sclerosis?. Biomarkers 19(7): 571-577, 2015

Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. Dementia and Geriatric Cognitive Disorders 44(3-4): 144-152, 2017

Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients. Neuromolecular Medicine 18(4): 551-560, 2016

Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment. Journal of Neuroinflammation 13(1): 131, 2017

Exploring microRNA Biomarker for Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 19(5), 2018

Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neuroscience Letters 416(3): 257-260, 2007

Cerebrospinal fluid proteins in the course of amyotrophic lateral sclerosis. Revue Neurologique 125(5): 393-400, 1971

Cerebrospinal fluid filtration in amyotrophic lateral sclerosis. European Journal of Neurology 6(5): 597-600, Sept, 1999

Cerebrospinal fluid cytotoxicity in lateral amyotrophic sclerosis. Neurologia 25(6): 364-373, 2011

Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. Journal of Neurology 231(2): 75-78, 1984

Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Experimental and Therapeutic Medicine 11(6): 2095-2106, 2016

Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochemical Research 33(11): 2358-2363, 2008

Cerebrospinal Fluid Oligoclonal Proteins in Amyotrophic Lateral Sclerosis. Archives of Neurology 36(2): 119-119, 1979